🇺🇸

Regulatory Compliance

· daily

US SEC Trading Suspension Halt Orders — June 26, 2026

The three filings in this trading suspension digest present a starkly divided micro-cap landscape on June 26, 2026. Two companies (Upexi and Matinas BioPharma) are actively fighting for their exchange listings, while a third (Outlook Therapeutics) has successfully resolved its delisting threat. The most critical development is the high materiality (9/10) of all three events, indicating significant binary risk for investors. Upexi faces a Nasdaq delisting notice due to a massive $187M convertible note issuance without shareholder approval, yet paradoxically gained inclusion in the Russell Microcap Index. Matinas BioPharma received a second NYSE American non-compliance notice with stockholders' equity at just $3.02M, but secured a long compliance plan through October 2027. Outlook Therapeutics provides a positive counterpoint, having regained Nasdaq compliance on bid price after a four-month struggle. The common thread is that all three companies are navigating severe financial distress or governance issues, with regulatory deadlines creating near-term catalysts. No period-over-period revenue or margin trends were available in these filings, as the focus was on listing compliance rather than operational performance.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — June 26, 2026

The three filings in this digest on trading suspensions, delistings, and regulatory halts reveal a stark bifurcation in micro-cap healthcare and technology companies. Two companies (Upexi and Matinas BioPharma) are actively fighting non-compliance, while one (Outlook Therapeutics) has successfully reversed its delisting risk. The key trend is the high frequency of non-compliance events tied to convertible note structures (Upexi) and sustained negative equity positions (Matinas), which are typical distress signals for micro-caps. Critically, enriched period-over-period data is absent from these filings, as they are event-driven 8-K filings rather than periodic reports; however, forward-looking data on compliance deadlines, insider trading (unavailable), and capital allocation (unavailable) still provides a high-stakes outlook. The most material development is the Russell Microcap Index addition for Upexi, which injects a positive catalyst into an otherwise dire delisting scenario. The sector theme is clear: small-cap biotech and tech firms face a tightening regulatory and capital environment, forcing a high rate of 'penny stock' distress.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — June 25, 2026

The two filings today represent a stark contrast in trading suspension/delisting outcomes within the Nasdaq ecosystem. Global Interactive Technologies (GITS) successfully resolved its compliance deficiency, confirming a de-listing risk reversal that provides a clean bill of health for its listing status. Conversely, Heron Therapeutics (HRTX) faces a new, acute price-based delisting threat, with its stock trading below the $1.00 minimum bid threshold. The key divergence lies in the root cause: GITS faced a procedural (filing) issue which was cured, while HRTX faces a fundamental market valuation challenge. The absence of strong insider buying or operational catalysts at Heron Therapeutics amplifies the risk of a forced reverse stock split and potential eventual delisting if the stock price fails to recover. The patterns highlight that while procedural compliance can be restored through administrative action, price-based non-compliance requires market-driven solutions, making it a more challenging obstacle.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — June 24, 2026

The three filings in this digest all involve US-listed companies facing severe delisting or trading suspension risks, underscoring a broader trend of micro-cap and small-cap distress. SRx Health Solutions (SRXH) is in a trading halt on NYSE American and has announced a 1-for-60 reverse stock split to regain compliance, but faces a high risk of delisting if the split fails to lift its stock price. Aditxt (ADTX) has received a final delisting determination from Nasdaq, with trading suspended effective June 25, 2026, after failing both the Bid Price Rule and Stockholders' Equity Requirement—its seventh reverse split attempt failed to maintain compliance. Definitive Healthcare (DH) received a non-compliance notice for the bid price rule but has a 180-day cure period and no immediate trading halt, making it the least acute of the three. Period-over-period data from the enriched filings reveals that all three companies have negative sentiment and no insider buying, while Aditxt's equity has deteriorated to -$35.2 million, a massive decline from the $2.5 million minimum. The key theme is a wave of reverse stock splits failing to cure structural compliance issues, signaling that these companies face fundamental business challenges beyond just low stock prices.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — June 23, 2026

On June 23, 2026, two micro-cap companies faced divergent regulatory outcomes from Nasdaq: TON Strategy Co (TONX) received a letter of reprimand for an equity plan violation but avoided delisting, while DevvStream Corp. (DEVS) received a final delisting determination for non-compliance with the minimum bid price and net income rules, with shares suspended effective June 24, 2026. The period-over-period analytics for both filings are sparse—no YoY/QoQ financial trends, insider trades, forward-looking guidance, or capital allocation data were reported, making sector-level trend aggregation impossible. Insider trading activity, capital allocation changes, and financial ratios were absent across both filings. Schedule events show a critical deadline for DEVS: trading suspension at Nasdaq open on June 24, 2026, with an appeal that will not stay suspension. The overarching theme is the binary risk of Nasdaq non-compliance: one company avoided delisting via self-reporting and corrective governance, while the other faces an immediate move to the Pink Limited Market. Market implications are strongest for DEVS, where the delisting is likely to trigger forced selling and price discovery in OTC markets.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — June 18, 2026

Two micro-cap biotech/life sciences companies received Nasdaq deficiency notices in the same week, signaling a potential sector-wide liquidity and compliance stress among small-cap listed firms. Algorhythm Holdings (RIME) received a bid price deficiency notice on June 16, 2026, with a 180-day cure period through December 14, 2026, and a possible extension, while Dyadic International (DYAI) received a delisting notice on June 18, 2026, after failing to cure its bid price deficiency and also failing to meet alternative continued listing standards (minimum $2.5M shareholders' equity). Both filings carry negative sentiment and high materiality (8/10 and 9/10), but Dyadic's situation is more acute due to the simultaneous failure of multiple listing requirements and the lack of an automatic extension. The clustering of these events suggests that many micro-cap companies are struggling to maintain Nasdaq listing standards amid a challenging capital-raising environment, and investors should monitor for a wave of similar deficiency notices.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — June 17, 2026

All three filings in this stream involve US-listed companies facing severe regulatory or financial distress, culminating in trading suspensions or delisting risks. Sleep Number Corp (SNBR) filed for Chapter 11 bankruptcy and received a Nasdaq delisting notice, with trading suspended June 23, 2026—a definitive end for equity holders. Gencor Industries (GENC) resolved a NYSE delinquency notice by filing its overdue 10-Q on June 12, 2026, and regained compliance on June 15, 2026, representing a positive turnaround from a near-delisting event. Vestand Inc. (VSTD) failed to regain compliance with Nasdaq's minimum bid price and remains non-compliant with multiple SEC filings, facing a hearings panel with no assurance of continued listing. Across the portfolio, two out of three companies (SNBR, VSTD) exhibit terminal negative sentiment and high materiality, while Gencor shows a mixed but resolved situation. No period-over-period comparisons, insider activity, forward-looking guidance, or capital allocation data were available in the enriched filings, limiting trend analysis. The key market implication is heightened risk for equity holders in distressed micro-cap and mid-cap names, with potential for complete loss in SNBR and VSTD.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — June 16, 2026

MaxCyte, Inc. regained compliance with Nasdaq's minimum bid price rule after its stock closed at $1.00 or above for 10 consecutive days, removing delisting risk. The positive resolution is a critical milestone for the company, but no other filings in this stream show similar regulatory actions. The lack of period-over-period comparisons, insider trading, or forward-looking data limits deeper trend analysis. The single filing highlights a company-specific event rather than a sector-wide pattern. Investors should monitor MaxCyte's stock price stability and any future compliance issues.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — June 15, 2026

The session is extremely quiet for US trading suspensions on June 15, 2026, with only two filings, both negative and highly material, signaling a wave of small-cap distress. Both Functional Brands Inc. and ESS Tech, Inc. received exchange notices threatening their listings due to persistently low stock prices, reflecting a broader 'sub-$1.00' crisis among micro-cap and pre-revenue companies. Functional Brands faces an imminent delisting from Nasdaq (suspension effective June 16) with no operational cure available, while ESS Tech has a six-month cure window under NYSE rules. Neither company shows signs of insider buying, capital allocation strength, or positive forward guidance to reverse the dilution spiral. The common thread is an inability to maintain minimum bid prices, with both companies likely needing reverse stock splits—a historically bearish signal for existing shareholders. No period-over-period revenue or margin trends were available from these regulatory filings, as they focus on stock price compliance rather than operational performance.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — June 12, 2026

Over the past 24 hours, 12 filings reveal a severe wave of Nasdaq and NYSE American trading suspensions and delisting risks, concentrated among micro-cap biotech and healthcare companies. The dominant theme is acute financial distress, with 10 out of 12 companies reporting negative equity or failing minimum bid price rules, and 6 receiving new deficiency notices on June 9-12, 2026. Period-over-period comparisons show a stark pattern: Soligenix's Phase 3 trial futility, La Rosa's negative equity of $(1.85M), and Wellgistics' $(12.45M) deficit highlight a sector-wide liquidity crisis. Insider activity is notably absent, with no insider buying detected across any filing, signaling a lack of management conviction. Forward-looking data reveals a compressed catalyst calendar: 7 companies face critical compliance deadlines between October and December 2026, with Genprex already ineligible for a grace period due to a prior reverse split. The most critical development is the NYSE American delisting of Perfect Moment Ltd., which chose not to appeal, setting a precedent for voluntary OTC transitions. The market implication is clear: investors should expect a cascade of delistings in H2 2026, with significant downside risk for common equity holders.

12 high priority 12 total filings
· daily

US SEC Trading Suspension Halt Orders — June 11, 2026

The sole filing in this stream, GoHealth, Inc.'s 8-K, signals a definitive and catastrophic end for its equity holders, with Nasdaq trading suspension set for June 16, 2026, following a Chapter 11 bankruptcy filing. The company's failure to meet Nasdaq's minimum market value requirement (Rule 5550(b)(2)) since March 2026, combined with the bankruptcy, triggered a delisting based on public interest concerns. Management's decision to not appeal and the explicit warning of 'limited recovery' for equity holders under the prepackaged plan underscores a total loss scenario. This event highlights the acute risk in micro-cap companies with unsustainable debt loads and provides a stark case study in the final stages of equity value destruction. No period-over-period trends, insider activity, or forward-looking guidance are available from this filing, as the focus is entirely on the cessation of trading and the bankruptcy process.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — June 10, 2026

The sole filing in today's trading suspension stream is from BIO-KEY International Inc., which has received an additional Nasdaq delisting notice due to a late 10-Q filing, compounding an earlier suspension threat from May 2026. Sentiment is heavily negative, with a materiality score of 9/10, indicating a high likelihood of trading cessation. The company has a critical hearing on June 16, 2026, to appeal, but no assurance of continued listing exists. No period-over-period comparisons, insider activity, or forward-looking financial guidance are available, limiting cross-company trends. The key development is the imminent regulatory decision, creating binary risk for shareholders.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — June 09, 2026

The session on June 9, 2026, was extremely quiet, with only two filings flagged for trading suspension risks, both involving Nasdaq bid price deficiencies. Both Professional Diversity Network (IPDN) and Jasper Therapeutics (JSPR) received deficiency notices for failing to maintain a $1.00 minimum bid price over 30 consecutive business days, a classic low-price distress signal. Neither filing contained period-over-period financial comparisons, insider trading activity, or forward-looking guidance, indicating these are purely procedural notifications with no new operational data. The key divergence is that Jasper, a biotech, has a more viable path to compliance via a reverse stock split and may qualify for a second 180-day cure period, while IPDN faces a more uncertain outlook given its smaller market cap and lack of disclosed remediation strategy. The overarching theme is a micro-cap distress pattern with no immediate trading halt, but both stocks carry high delisting risk if they fail to cure by late 2026.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — June 08, 2026

The single filing in this intelligence stream, from aTyr Pharma, highlights a critical delisting risk due to non-compliance with Nasdaq's minimum bid price rule. The company has received a second 180-day compliance period, extending the deadline to November 30, 2026, but there is no assurance of success. The negative sentiment and high materiality score (8/10) underscore the severity of the situation for shareholders. No period-over-period comparisons, insider activity, or forward-looking guidance were available in the enriched data, limiting the depth of trend analysis. The key development is the company's failure to meet the initial deadline and its reliance on a second grace period, which introduces significant uncertainty. The market implication is a heightened risk of a sudden trading suspension and potential delisting, which would severely impact liquidity and valuation.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — June 05, 2026

On June 5, 2026, three US-listed companies disclosed Nasdaq non-compliance notices, signaling a concentrated wave of regulatory risk in the small-cap and micro-cap space. The filings reveal a common theme of deteriorating market valuation and liquidity, with two companies (Arrive AI and Research Frontiers) failing the minimum $1.00 bid price rule and one (Driven Brands) failing timely filing requirements for the second consecutive quarter. Period-over-period data is limited as these are event-driven 8-Ks, but the recurrence of Driven Brands' filing delays (previously resolved May 19, 2026) indicates systemic internal control weaknesses. Research Frontiers faces a dual deficiency (bid price and market value of listed securities) and has explicitly ruled out a reverse stock split, increasing delisting risk. No insider trading activity or capital allocation changes were reported, suggesting management is in a holding pattern. The aggregate market implication is heightened delisting risk for three distinct companies, each with 180-day compliance windows ending November 30, 2026, creating a catalyst calendar for investors monitoring turnaround or exit strategies.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — June 04, 2026

The four filings reveal a concentrated wave of Nasdaq and NYSE American compliance failures, with three newly reported incidents (Smith-Midland, Veea, and Abpro Holdings) and one ongoing plan acceptance (Volato Group). All carry negative sentiment, but materiality varies: Abpro Holdings faces final delisting to OTC Pink (highest risk), while Smith-Midland and Veea have cure periods with no immediate trading impact. Period-over-period trends are absent in these filings (no financial statements), but the pattern of regulatory non-compliance across small/mid-cap issuers is striking—three of four companies are emerging growth firms with limited financial resources. Insider trading activity is not disclosed in any filing, but the sudden board member death at Veea introduces governance risk. Capital allocation data is missing, but the lack of buyback or dividend activity suggests financial strain. The key takeaway: a cluster of micro-cap listings is under regulatory pressure, creating potential short-selling opportunities and distressed asset plays for risk-tolerant investors.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — June 03, 2026

The June 3, 2026 trading suspension intelligence stream reveals two distinct events: a high-risk compliance delisting for Reed's, Inc. (REED) on NYSE American, and a voluntary, low-risk exchange transfer for Fifth Third Bancorp (FITB) from Nasdaq to NYSE. Reed's faces a material threat after failing NYSE American's stockholders' equity thresholds, triggering a '.BC' trading designation and a tight 30-day plan deadline, representing a 9/10 materiality risk for shareholders. Conversely, Fifth Third's move is purely administrative with no compliance failure, resulting in a neutral 5/10 materiality, offering a seamless transition for investors. No period-over-period financial comparisons or insider trading data were provided in these filings, so the focus is on regulatory mechanics and timeline-driven risks. The absence of cross-cutting capital allocation or forward-looking guidance limits deep trend analysis, but the calendar of deadlines is critical for Reed's holders.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — June 02, 2026

The two filings highlight contrasting regulatory trajectories for US-listed companies, with one voluntarily exiting the NYSE for Nasdaq and the other fighting to maintain its Nasdaq listing amid compliance struggles. LendingClub's voluntary transfer to Nasdaq with a new ticker 'HAPN' signals a strategic rebranding to 'Happen, Inc.' and the launch of Happen Bank, but the move lacks financial context or performance data, leaving materiality moderate. In contrast, Triller Group faces a high-stakes deadline (June 30, 2026) to meet Nasdaq's $1.00 bid price rule, having already survived a prior suspension over periodic filings. The absence of insider trading activity or period-over-period financial comparisons in both filings limits trend analysis, but Triller's repeated successful appeals suggest a pattern of regulatory resilience. No portfolio-level trends emerge due to the small sample size, but the divergence between proactive and reactive listing strategies is notable. The market implications are binary: Triller's potential delisting could trigger a sharp sell-off, while LendingClub's transfer may see minimal disruption given its voluntary nature.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — June 01, 2026

This intelligence stream covers four US-listed companies that received trading suspension or delisting notices from Nasdaq and NYSE American between May 19 and May 29, 2026. All four filings carry negative sentiment, with materiality scores ranging from 8 to 9 out of 10, indicating high risk of trading disruption. The primary causes are regulatory non-compliance: two companies (NusaTrip and Gencor Industries) failed to file periodic reports on time, while HCW Biologics and iSpecimen face minimum bid price and stockholders' equity deficiencies, respectively. No period-over-period financial trends or insider trading activity were disclosed in these filings, as they focus solely on regulatory notices. The filings reveal a common pattern of companies relying on compliance plans and appeal processes to avoid immediate delisting, with deadlines ranging from 45 to 180 days. The most critical development is HCW Biologics' strict extension conditions, including immediate delisting if the bid price deficiency recurs before September 22, 2026. Market implications are significant: investors face potential liquidity events and price volatility as these companies navigate regulatory hurdles. No forward-looking guidance, capital allocation changes, or transaction details were reported, underscoring the reactive nature of these filings.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — May 29, 2026

This intelligence digest synthesizes 9 pre-analyzed SEC filings from May 29, 2026, all concerning trading suspensions and delisting risks on US exchanges. A dominant theme is the widespread failure to meet Nasdaq's minimum stockholders' equity requirement, with three companies (Aditxt, Onfolio, HWH International) reporting negative or critically low equity, and a fourth (Actinium Pharmaceuticals) falling short of NYSE American's $4.0 million threshold. Another cluster involves delayed periodic filings (Fathom, Gulf Resources, Clean Energy Technologies, Cloudastructure), indicating systemic reporting control issues. The most acute risk is for Edible Garden AG, which faces an imminent suspension on June 5, 2026, due to ineligibility for a compliance period after multiple reverse stock splits. While most filings carry negative sentiment, Actinium Pharmaceuticals presents a mixed picture, balancing a delisting notice with a positive clinical program update, offering a potential turnaround catalyst. The aggregate data reveals a micro-cap distress pattern, with all affected companies having market capitalizations well below $100 million and exhibiting negative equity or recurring losses, signaling a high-risk environment for investors in this segment.

9 high priority 9 total filings